These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 11448286)
21. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ; Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251 [TBL] [Abstract][Full Text] [Related]
22. Management of HIV infection after triple class failure. Cossarini F; Spagnuolo V; Gianotti N; Carbone A; Lazzarin A; Castagna A New Microbiol; 2013 Jan; 36(1):23-39. PubMed ID: 23435813 [TBL] [Abstract][Full Text] [Related]
23. The amplitudes of viral blips in HIV-1 infected patients treated with antiretroviral therapy are power-law distributed. Percus JK; Percus OE; Di Mascio M J Theor Biol; 2009 Apr; 257(3):454-9. PubMed ID: 19171155 [TBL] [Abstract][Full Text] [Related]
24. Low-level viremia is associated with non-B subtypes in patients infected with HIV with virological success following HAART introduction. Saison J; Tardy JC; Scholtes C; Icard V; Trabaud MA; Perpoint T; Chidiac C; Ecochard R; André P; Ferry T; J Med Virol; 2013 Jun; 85(6):953-8. PubMed ID: 23588720 [TBL] [Abstract][Full Text] [Related]
25. Can HIV infection be eradicated through use of potent antiviral agents? Josefsson L; Dahl V; Palmer S Curr Opin Infect Dis; 2010 Dec; 23(6):628-32. PubMed ID: 20847693 [TBL] [Abstract][Full Text] [Related]
26. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml. Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049 [TBL] [Abstract][Full Text] [Related]
27. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Laprise C; de Pokomandy A; Baril JG; Dufresne S; Trottier H Clin Infect Dis; 2013 Nov; 57(10):1489-96. PubMed ID: 23946221 [TBL] [Abstract][Full Text] [Related]
28. Trajectory analyses of virologic outcomes reflecting community-based HIV treatment in Washington DC 1994-2012. Ocampo JM; Plankey M; Zou K; Collmann J; Wang C; Young MA; Liu C; Ripple JA; Kassaye S BMC Public Health; 2015 Dec; 15():1277. PubMed ID: 26695971 [TBL] [Abstract][Full Text] [Related]
29. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects]. Marcello A; Giacca M Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891 [No Abstract] [Full Text] [Related]
30. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. Havlir DV; Koelsch KK; Strain MC; Margot N; Lu B; Ignacio CC; Miller MD; Wong JK; J Infect Dis; 2005 Apr; 191(7):1164-8. PubMed ID: 15747253 [TBL] [Abstract][Full Text] [Related]
31. [Impact of new antiretroviral therapy in HIV infected patients with virologic failure]. Costagliola D Med Sci (Paris); 2012; 28(8-9):706-7. PubMed ID: 22920871 [No Abstract] [Full Text] [Related]
32. Slow or fast viral load decay as a predictor of residual viremia level in HIV-infected patients undergoing successful first-line cART. Amendola A; Bibbolino G; Navarra A; Pisciotta M; Marsella P; Pinnetti C; Abbate I; Rozera G; Mondi A; Antinori A; Capobianchi MR; Girardi E; Ammassari A New Microbiol; 2017 Oct; 40(4):234-241. PubMed ID: 29184963 [TBL] [Abstract][Full Text] [Related]
33. Exploring the benefits and limits of highly active antiretroviral therapy. D'Aquila R; Walker B JAMA; 1999 Nov; 282(17):1668-9. PubMed ID: 10553795 [No Abstract] [Full Text] [Related]
34. Down or out in blood and lymph? Wain-Hobson S Nature; 1997 May; 387(6629):123-4. PubMed ID: 9144275 [No Abstract] [Full Text] [Related]
35. Running with scissors: using antiretroviral therapy without monitoring viral load. Smith DM; Schooley RT Clin Infect Dis; 2008 May; 46(10):1598-600. PubMed ID: 18419496 [No Abstract] [Full Text] [Related]
37. HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART. Lombardi F; Belmonti S; Rapone L; Borghetti A; Ciccullo A; Gagliardini R; Baldin G; Montagnani F; Moschese D; Emiliozzi A; Rossetti B; De Luca A; Di Giambenedetto S J Clin Virol; 2018 Jun; 103():57-62. PubMed ID: 29656086 [TBL] [Abstract][Full Text] [Related]
38. HIV-1 DNA and RNA kinetics in primary HIV infection. Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174 [TBL] [Abstract][Full Text] [Related]
39. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Colebunders R; Moses KR; Laurence J; Shihab HM; Semitala F; Lutwama F; Bakeera-Kitaka S; Lynen L; Spacek L; Reynolds SJ; Quinn TC; Viner B; Mayanja-Kizza H Lancet Infect Dis; 2006 Jan; 6(1):53-9. PubMed ID: 16377535 [TBL] [Abstract][Full Text] [Related]
40. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]